Complete response letters

Summit Therapeutics Inc. · BLA 761524

yy U.S. FOOD & DRUG ADMINISTRATION BLA 761524 COMPLETE RESPONSE Summit Therapeutics Inc. Attention: Darshan Gandhi Associate Director, Regulatory Affairs 601 Brickell Key Drive, Suite 1000 Miami, FL…

COMPLETE RESPONSEUnapproved
Letter date
11/13/2026
File name
CRL_BLA761524_20261113.pdf
Letter year
2026
Approval status
Unapproved
Approver name
Center for Drug Evaluation and Research
Company rep
Darshan Gandhi
Company address
601 Brickell Key Drive, Suite 1000 Miami, FL 33131
Company name
Summit Therapeutics Inc.
Letter type
COMPLETE RESPONSE
Text

¢ yy U.S. FOOD & DRUG ADMINISTRATION BLA 761524 COMPLETE RESPONSE Summit Therapeutics Inc. Attention: Darshan Gandhi Associate Director, Regulatory Affairs 601 Brickell Key Drive, Suite 1000 Miami, FL 33131 Dear Darshan Gandhi: Please refer to your biologics license application (BLA) dated and received November 14, 2025, and your amendments, submitted under me) for AK112/SMT112 (also referred to by the Applicant as ivonescimab). We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. CLINICAL/STATISTICAL Substantial evidence of effectiveness is not established and the benefit-risk profile does not support approval. 1. The applicability of the prespecified primary endpoint of progression-free survival (PFS) to the US population cannot be established as 93% of events (257 of 275 PFS events) occurred in patients enrolled in China. As communicated at the Type A meeting (March 2023) and reaffirmed at the Pre-BLA meeting (May 2025), the Agency had previously discussed concerns regarding the enrollment approach for the clinical trial, which was originally designed as a single country trial with enrollment exclusively in China and subsequently modified to include enrollment from North America (NA) and the European Union (EU). The trial enrolled (" patients in China (60% of the study population) from January 2022 to November 2022, and enrollment of patients from NA and EU regions did not commence until May 2023. 2. The primary endpoint of PFS, while statistically significant, demonstrated a modest improvement in median PFS in the context of an add-on to chemotherapy, with no statistically significant improvement in final overall survival (OS) and no substantial difference in overall response rate (ORR). Reference ID: 5904014 BLA 761524 Page 2 3. The submitted post-hoc analyses of PFS and OS based on longer follow-up are exploratory only with post-hoc analyses of OS further limited by differential data cutoff (DCO) dates across regions. These differential DCO dates appear to be due to termination of follow-up at an earlier date for patients enrolled in China compared to patients enrolled in NA and EU, with clinical sites in China closing during 2025. 4. The modest improvement in median PFS does not outweigh the risks of ivonescimab as an add-on to chemotherapy, given that patients with EGFR- mutated non-small cell lung cancer treated with ivonescimab would be exposed to additional toxicities, including serious immune-related toxicities and toxicities related to VEGF inhibition. Recommendation: Submit results from a new adequate and well-controlled multiregional clinical trial consistent with ICH E17 and FDA guidance for industry, Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs, demonstrating a statistically significant and clinically meaningful improvement in overall survival, progression-free survival or another endpoint that measures Clinical benefit, sufficient to outweigh the observed toxicity profile. We recommend you meet with us prior to initiating a new trial to discuss the proposed study design and endpoints. PRESCRIBING INFORMATION We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) - a checklist of important format items from labeling regulations and guidances. CARTON AND CONTAINER LABELING We reserve comment on the proposed labeling until the application is otherwise adequate. PROPRIETARY NAME Please refer to our correspondence dated February 10, 2026, which addresses the proposed proprietary name, |). This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the 1 https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources 2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs- final-rule U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5904014 BLA 761524 Page 3 proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter. SAFETY UPDATE When you respond to the above deficiencies, include a safety update. The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level. 5. 6. 10. 11. Describe in detail any significant changes or findings in the safety profile. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows: e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission. e Present tabulations of the new safety data combined with the original application data. e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above. e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials. Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified. Provide case report forms and narrative summaries for each subject who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data. Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time). Provide a summary of worldwide experience on the safety of this product. Include an updated estimate of use for product marketed in other countries. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5904014 BLA 761524 Page 4 12. Provide English translations of current approved foreign labeling not previously submitted. OTHER Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application. A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle. You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. The product may not be legally marketed until you have been notified in writing that this application is approved. NOTICE REGARDING PUBLIC DISCLOSURE Consistent with FDA's public statements regarding its Complete Response Letter disclosure initiative, the Agency is working to redact and publish this Complete Response Letter on the FDA website, as appropriate. Should this Complete Response Letter be publicly disclosed, FDA will redact trade secret information, confidential commercial information, and personally identifiable information consistent with 21 CFR Part 20 prior to publication. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5904014 BLA 761524 Page 5 If you have any questions, contact Sincerely, {See appended electronic signature page} Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5904014 Signature Page 1 of 1 This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. (b) (4) 11/13/2026 02:08:40 PM Reference ID: 5904014

Application number
BLA 761524
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.